Esperion Therapeutics, Inc. (ESPR)
2.67
-0.10
(-3.61%)
USD |
NASDAQ |
Mar 06, 10:55
Esperion Therapeutics Cash from Investing (Quarterly) : 0.00 for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Nektar Therapeutics | -94.87M |
| Rigel Pharmaceuticals, Inc. | -25.36M |
| Harrow, Inc. | -4.73M |
| AnaptysBio, Inc. | 73.50M |
| ACADIA Pharmaceuticals, Inc. | -55.87M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -4.286M |
| Cash from Financing (Quarterly) | 10.67M |
| Free Cash Flow | -93.29M |
| Free Cash Flow Per Share (Quarterly) | -0.0214 |
| Free Cash Flow to Equity (Quarterly) | -7.093M |
| Free Cash Flow to Firm (Quarterly) | 17.76M |
| Free Cash Flow Yield | -17.69% |